(RTTNews) - On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
